Novel long-lasting interferon alpha derivatives designed by glycoengineering

Biochimie

Volumn 90, Issue 3, 2008, Pages 437-449

  Ceaglio, N ^a   Etcheverrigaray, M ^a   Kratje, R ^a   Oggero, M ^a  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

Author keywords

Interferon alpha 2b; Mutein; N glycosylation; Serum half life

Indexed keywords

ALPHA2 INTERFERON; CARBOHYDRATE; CYTOKINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MUTAGENESIS; NONHUMAN; RAT; SEQUENCE ANALYSIS;

ANIMALS; BINDING SITES; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; GLYCOSYLATION; HUMANS; INTERFERON ALFA-2B; MUTATION; PROTEIN ENGINEERING; RATS;

RATTUS;

EID: 39149098790     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2007.10.013     Document Type: Article

References (62)

1. Isaacs A., and Lindenmann J. Virus interference I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147 (1957) 258-267
2. Krim M. Towards tumor therapy with interferons, part I. Interferons: production and properties. Blood 55 5 (1980) 711-721
3. Bekisz J., Schmeisser H., Hernandez J., Goldman N., and Zoon K. Human interferons alpha, beta and omega. Growth factors 22 4 (2004) 243-251
4. De Maeyer E., and De Maeyer-Guignard J. Interferons. In: Thomson A.W. (Ed). The Cytokine Handbook (1994), Academic Press, New York 265-288
5. Goodbourn S., Didcock L., and Randall R.E. Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81 (2000) 2341-2364
6. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., and Layden T.J. A.S. Perelson, Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282 5386 (1998) 103-107
7. Goldstein D., and Laszlo J. Interferon therapy in cancer: from imaginon to interferon. Cancer Res. 46 (1986) 4315-4329
8. Borden E.C., Lindner D., Dreicer R., Hussein M., and Peereboom D. Second-generation interferon for cancer: clinical targets. Semin. Cancer Biol. 10 (2000) 125-144
9. Chatelut E., Rostaing L., Grégoire N., Payen J., Pujol A., Izopet J., Houin G., and Canal P. A pharmacokinetic model for alpha interferon administered subcutaneously. J. Clin. Pharmacol. 47 (1999) 365-371
10. Gutterman J.U. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. U.S.A. 94 (1994) 1198-1205
11. Wang Y., Youngster S., Grace M., Bausch J., Bordens R., and Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54 (2002) 547-570
12. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W., Porter J.E., Ehrlich G.K., Pan W., Xu Z., Modi M.W., Farid A., and Berthold W. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethyleneglycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem. 12 (2001) 195-202
13. Elliot S., Lorenzini T., Asher S., Aoki K., Brankow D., Buck L., Busse L., Chang D., Fuller J., Grant J., Hernday N., Hokum M., Hu S., Knudten A., Levin N., Komorowski R., Martin F., Navarro R., Osslund T., Rogers G., Rogers N., Trail G., and Egrie J. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol. 21 (2003) 414-421
14. Sinclair A.M., and Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94 8 (2005) 1626-1635
15. Gooche C.F., Gramer M.J., Andersen D.C., Bahr J.B., and Rasmussen J.R. The oligosaccharides of glycoproteins: factors affecting their synthesis and their influence on glycoprotein properties. Biotechnology 9 (1992) 1347-1355
16. Morell A.G., Gregoriadis G., and Scheinberg H. The role of sialic acid in determining the survival of glycoproteins in the circulation. J. Biol. Chem. 246 5 (1971) 1461-1467
17. Koury M.J. Sugar coating extends half-life and improves effectiveness of cytokine hormones. Trends Biotechnol. 21 11 (2003) 462-464
18. Jenkins N., and Curling E.M.A. Glycosylation of recombinant proteins: problems and prospects. Enzyme Microb. Technol. 16 (1994) 354-364
19. Bino T., Madar Z., Gertler A., and Rosenberg H. The kidney is the main site of interferon degradation. J. Interferon Res. 2 29 (1982) 301-308
20. Peleg-Shulman T., Tsubery H., Mironchik M., Fridkin M., Schreiber G., and Shechter Y. Reversible PEGylation: a novel technology to release native interferon α2 over a prolonged time period. J. Med. Chem. 47 (2004) 4897-4904
21. Montreuil J., Bouquelet S., Debray H., Lemoine J., Michalski J., Spik G., and Strecker G. Glycoproteins. In: Chaplin M.F., and Kennedy J.K. (Eds). Carbohydrate Analysis. A Practical Approach (1994), Oxford University Press, Oxford, UK 181-293
22. Restelli V., and Butler M. The effect of cell culture parameters on protein glycosylation. In: Al-Rubeai M. (Ed). Cell Engineering. Glycosylation Vol. 3 (2002), Kluwer Academic Publishers, Dordrecht, The Netherlands 61-92
23. Kratje R.B., and Wagner R. Evaluation of production of recombinant human interleukin-2 in fluidized bed bioreactor. Biotechnol. Bioeng. 39 (1992) 233-242
24. Galfrè G., and Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol. 73 (1981) 3-46
25. Friguet B., Chaffotte A.F., Djavadi-Ohaniance L., and Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77 (1985) 305-319
26. Harlow E., and Lane D. Antibodies. A Laboratory Manual (1988), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 53-137
27. Kuroki M. A simple solid-phase competition assay with labeled antigen. In: Morris G.E. (Ed). Methods in Molecular Biology. Epitope Mapping Protocols Vol. 66 (1996), Humana Press Inc., Totowa, NJ 47-53
28. Radhakrishnan R., Walter L.J., Hruza A., Reichert P., Trotta P.P., Nagabhushan T.L., and Walter M.R. Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography. Structure 4 12 (1996) 1453-1463
29. 2a determined by heteronuclear NMR spectroscopy in solution. J. Mol. Biol. 274 (1997) 661-675
30. Ahmad S., Gromiha M., Fawareh H., and Sarai A. ASAview: database and tool for solvent accessibility representation in proteins. BMC Bioinformatics 5 (2004) 51-55. http://www.netasa.org/asaview/
31. Gupta R., and Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pac. Symp. Biocomput. (2002) 310-322. http://www.cbs.dtu.dk/services/NetNGlyc/
32. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., and Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77 1 (1989) 51-59
33. Freshney R.I. Culture of Animal Cells. A Manual of Basic Technique. In: Freshney R.I. (Ed). Cloning and selection. fourth ed. (2000), Wiley-Liss Inc., Hoboken, NJ 195-215
34. Familletti P.C., Rubinstein S., and Petska S. A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol. 78 (1981) 387-394
35. Rubinstein S., Familletti P.C., and Pestka S. Convenient assay for interferons. J. Virol. 37 2 (1981) 755-758
36. Nederman T., Karlström E., and Sjödin L. An in vitro bioassay for quantitation of human interferons by measurements of antiproliferative activity on a continuous human lymphoma cell line. Biologicals 18 1 (1990) 29-34
37. Jones J., Krag S.S., and Betenbaugh M.J. Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta 1726 (2005) 121-137
38. Shakin-Eshleman S.H., Spitalnik S.L., and Kasturi L. The amino acid at the X position of an Asn-X-Ser sequon is an important determinant of N-linked core-glycosylation efficiency. J. Biol. Chem. 271 11 (1996) 6363-6366
39. Adolf G.R., Kalsner I., Ahorn H., Maurer-Fogy I., and Cantell K. Natural human interferon-α2 is O-glycosylated. Biochem. J. 276 (1991) 511-518
40. Piehler J., Roisman L.C., and Schreiber G. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface. J. Biol. Chem. 275 (2000) 40425-40433
41. Roisman L.C., Piehler J., Trosset J., Scheraga H.A., and Schreiber G. Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docking. Proc. Natl. Acad. Sci. U.S.A. 98 23 (2001) 13231-13236
42. Nilsson I., and von Heijne G. Glycosylation efficiency of Asn-Xaa-Thr sequons depends both on the distance from the C terminus and on the presence of a downstream transmembrane segment. J. Biol. Chem. 275 23 (2000) 17338-17343
43. Trombetta E.S., and Parodi A.J. Quality control and protein folding in the secretory pathway. Annu. Rev. Cell. Dev. Biol. 19 (2003) 649-676
44. Wu J.C., Liang Z.Q., and Qin Z.H. Quality control system of the endoplasmic reticulum and related diseases. Acta Biochim. Biophys. Sin. 38 4 (2006) 219-226
45. Gavel Y., and von Heijne G. Sequence differences between glycosylated and non-glycosylated Asn-X.Thr/Ser acceptor sites: implications for protein engineering. Protein Eng. 3 5 (1990) 433-442
46. Zoon K., Miller D., Bekisz J., zur Nedden D., Enterline J.C., Nguyen N.Y., and Hu R. Purification and characterization of multiple components of human lymphoblastoid interferon-α. J. Biol. Chem. 267 21 (1992) 15210-15216
47. Rossmann C., Sharp N., Allen G., and Gewert D. Expression and purification of recombinant, glycosylated human interferon alpha 2b in murine myeloma NS0 cells. Protein Expr. Purif. 7 (1996) 335-342
48. Evinger M., Rubinstein M., and Pestka S. Antiproliferative and antiviral activities of human leukocyte interferons. Arch. Biochem. Biophys. 210 1 (1981) 319-329
49. Roisman L.C., Jaitin D.A., Baker D.P., and Schreiber G. Mutational analysis of the IFNAR1 binding site on IFN-α2 reveals the architecture of a weak ligand-receptor binding-site. J. Mol. Biol. 353 (2005) 271-281
50. Jaitin D.A., Roisman L.C., Jaks E., Gavutis M., Piehler J., Van Der Heyden J., Uzé G., and Schreiber G. Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol. Cell. Biol. 26 5 (2006) 1888-1897
51. Karpusas M., Whitty A., Runkel L., and Hochman P. The structure of human interferon-β: implications for activity. Cell. Mol. Life Sci. 54 (1998) 1203-1216
52. Runkel L., Pfeffer L., Lewerenz M., Monneron D., Yang C.H., Murti A., Pellegrini S., Goelz S., Uzé G., and Mogensen K. Differences in activity between α and β type I interferons explored by mutational analysis. J. Biol. Chem. 273 14 (1998) 8003-8008
53. Ghislain J., Sussman G., Goelz S., Ling L.E., and Fish E.N. Configuration of the interferon-α/β receptor complex determines the context of the biological response. J. Biol. Chem. 270 37 (1995) 21785-21792
54. Kontsek P. Human type I interferons: structure and function. Acta Virol. 38 (1994) 345-360
55. MacDougall I.C., Gray S.J., Elston O., Breen C., Jenkins B., Browne J., and Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alpha in dialysis patients. J. Am. Soc. Nephrol. 10 (1999) 2392-2395
56. Perlmann S., van den Hazel B., Christiansen J., Gram-Nielsen S., Jeppesen C.B., Andersen K.V., Halkier T., Okkels S., and Schambye H.T. Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. J. Clin. Endocrinol. Metab. 88 7 (2003) 3227-3235
57. Slaton J.W., Perrotte P., Inoue K., Dinney C.P.N., and Fidler I.J. Interferon-α mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5 (1999) 2726-2734
58. Baker D.E. Pegylated interferons. Rev. Gastroenterol. Disord. 1 2 (2001) 87-99
59. Elliot S., Chang D., Delorme E., Eris T., and Lorenzini T. Structural requirements for additional N-linked carbohydrate on recombinant human erythropoietin. J. Biol. Chem. 279 16 (2004) 16854-16862
60. Kornfeld R., and Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54 (1985) 631-664
61. Egrie J.C., and Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant 16 3 (2001) 3-13
62. Pedder S.C.J. Pegylation of interferon alpha: structural and pharmacokinetic properties. Semin. Liver Dis. 23 Suppl. 1 (2003) 19-22